Functional cardiomyocytes from human stem cells: a tool for determining the cardiotoxic potential of preclinical drugs

Future Medicinal ChemistryVol. 5, No. 4 EditorialFunctional cardiomyocytes from human stem cells: a tool for determining the cardiotoxic potential of preclinical drugsNaama Zeevi-Levin, Joseph Itskovitz-Eldor & Ofer BinahNaama Zeevi-Levin* Author for correspondenceThe Berlin Family Laboratory for Stem Cell Research in The Sohnis & Forman Families Stem Cell Center for Stem Cell & Tissue Regeneration Research, The Ruth & Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, PO Box 9649, Haifa 31096, Israel. Search for more papers by this authorEmail the corresponding author at naama1@tx.technion.ac.il, Joseph Itskovitz-EldorThe Berlin Family Laboratory for Stem Cell Research in The Sohnis & Forman Families Stem Cell Center for Stem Cell & Tissue Regeneration Research, The Rappaport Faculty of Medicine & Research Institute, Technion, Israel Institute of Technology, Haifa, Israel and Department of Obstetrics & Gynecology, Rambam Health Care Campus, Haifa, IsraelSearch for more papers by this author & Ofer BinahThe Sohnis & Forman Families Stem Cell Center for Stem Cell & Tissue Regeneration Research, The Department of Physiology, The Rappaport Faculty of Medicine & Research Institute, Technion, Israel Institute of Technology, Haifa, IsraelSearch for more papers by this authorPublished Online:15 Mar 2013https://doi.org/10.4155/fmc.13.22AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: cardiomyocytesdrug discoverydrug screeninghuman pluripotent stem cellsReferences1 Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov.3(8),711–715 (2004).Crossref, Medline, CAS, Google Scholar2 Rajamohan D, Matsa E, Kalra S et al. Current status of drug screening and disease modeling in human pluripotent stem cells. Bioessays35(3),281–298 (2013).Crossref, Medline, CAS, Google Scholar3 Rubin LL. Stem cells and drug discovery: the beginning of a new era? Cell132(4),549–552 (2008).Crossref, Medline, CAS, Google Scholar4 Hughes B. 2008 FDA drug approvals. Nat. Rev. Drug Discov.8(2),93–96 (2009).Crossref, Medline, Google Scholar5 Braam SR, Tertoolen L, Van De Stolpe A, Meyer T, Passier R, Mummery CL. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res.4(2),107–116 (2010).Crossref, Medline, CAS, Google Scholar6 Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med.352(11),1092–1102 (2005).Crossref, Medline, CAS, Google Scholar7 Meyer T, Leisgen C, Gonser B, Gunther E. QT-screen: high-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes. Assay Drug Dev. Technol.2(5),507–514 (2004).Crossref, Medline, CAS, Google Scholar8 Jonsson MK, Van Veen TA, Goumans M-J, Vos MA, Duker G, Sartipy P. Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell-derived cardiomyocytes. Expert Opin. Drug Discov.4(4),357–372 (2009).Crossref, Medline, CAS, Google Scholar9 Pouton CW, Haynes JM. Embryonic stem cells as a source of models for drug discovery. Nat. Rev. Drug Discov.6(8),605–616 (2007).Crossref, Medline, CAS, Google Scholar10 Bollini S, Smart N, Riley PR. Resident cardiac progenitor cells: at the heart of regeneration. J. Mol. Cell. Cardiol.50(2),296–303 (2011).Crossref, Medline, CAS, Google Scholar11 Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science282(5391),1145–1147 (1998).Crossref, Medline, CAS, Google Scholar12 Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell126(4),663–676 (2006).Crossref, Medline, CAS, Google Scholar13 Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science318(5858),1917–1920 (2007).Crossref, Medline, CAS, Google Scholar14 Kehat I, Kenyagin-Karsenti D, Snir M et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest.108(3),407–414 (2001).Crossref, Medline, CAS, Google Scholar15 Zwi L, Caspi O, Arbel G et al. Cardiomyocyte differentiation of human induced pluripotent stem cells. Circulation120(15),1513–1523 (2009).Crossref, Medline, CAS, Google Scholar16 Laflamme MA, Chen KY, Naumova AV et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol.25(9),1015–1024 (2007).Crossref, Medline, CAS, Google Scholar17 Yang L, Soonpaa MH, Adler ED et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature453(7194),524–528 (2008).Crossref, Medline, CAS, Google Scholar18 Zhang J, Klos M, Wilson GF et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ. Res.111(9),1125–1136 (2012).Crossref, Medline, CAS, Google Scholar19 Zeevi-Levin N, Itskovitz-Eldor J, Binah O. Cardiomyocytes derived from human pluripotent stem cells for drug screening. Pharmacol. Ther.134(2),180–188 (2012).Crossref, Medline, CAS, Google Scholar20 Peng S, Lacerda AE, Kirsch GE, Brown AM, Bruening-Wright A. The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J. Pharmacol. Toxicol. Methods61(3),277–286 (2010).Crossref, Medline, CAS, Google Scholar21 Andersson H, Steel D, Asp J et al. Assaying cardiac biomarkers for toxicity testing using biosensing and cardiomyocytes derived from human embryonic stem cells. J. Biotechnol.150(1),175–181 (2010).Crossref, Medline, CAS, Google Scholar22 Ma J, Guo L, Fiene SJ et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol.301(5),H2006–H2017 (2011).Crossref, Medline, CAS, Google Scholar23 Pera MF. Stem cells: the dark side of induced pluripotency. Nature471(7336),46–47 (2011).Crossref, Medline, CAS, Google Scholar24 Zhang J, Wilson GF, Soerens AG et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res.104(4),e30–e41 (2009).Crossref, Medline, CAS, Google Scholar25 He JQ, Ma Y, Lee Y, Thomson JA, Kamp TJ. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ. Res.93(1),32–39 (2003).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByDual Function of iPSC-Derived Pericyte-Like Cells in Vascularization and Fibrosis-Related Cardiac Tissue Remodeling In Vitro25 November 2020 | International Journal of Molecular Sciences, Vol. 21, No. 23The importance of drug discovery for treatment of cardiovascular diseasesCharles Kennedy15 March 2013 | Future Medicinal Chemistry, Vol. 5, No. 4 Vol. 5, No. 4 Follow us on social media for the latest updates Metrics Downloaded 89 times History Published online 15 March 2013 Published in print March 2013 Information© Future Science LtdKeywordscardiomyocytesdrug discoverydrug screeninghuman pluripotent stem cellsFinancial & competing interests disclosureThis work was supported by the Israel Science Foundation, Ministry of Health – Chief Scientist, the Rappaport Family Institute for Research in the Medical Sciences, The Sohnis and Forman Families Stem Cells Center, and NIH grant 1R01HL111401-01. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download